Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 5, 2000, Pages 423-427

  Roberts, John D ^a   Shibata, Stephen ^b   Spicer, Darcy V ^c   McLeod, Howard L ^d   Tombes, Mary Beth ^a   Kyle, Brenda ^a   Carroll, Mary ^b   Sheedy, Beth ^e   Collier, Mary A ^e   Pithavala, Yazdi K ^e   Paradiso, Linda J ^e   Clendeninn, Neil J ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

AG2034; Glycinamide ribonucleotide transformylase inhibitor; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034007649     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051012     Document Type: Article

References (16)

1. 1. Jackson RC, Harkrader RJ (1981) The contributions of the de novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. In: Tattersall MHN, Fox RM (eds) Nucleosides and cancer treatment. Academic Press, Sydney, pp 18-31
2. 2. Beardsley GP, Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J Biol Chem 264: 328-333
3. 3. Shih C, Grindey GB, Houghton PJ, Houghton JA (1980) In vivo antitumor activity of 5,10-dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers. Proc Am Assoc Cancer Res 29: 283
4. 4. Taylor EC (1990) New pathways from pteridines. Design and synthesis of a new class of potent and selective antitumor agents. J Heterocycl Chem 27: 11
5. 5. Young CW, Currie VE, Muindi JF, Saltz LB, Pisters KMW, Esposito AJ, Dyke RW (1992) Improved clinical tolerance of lometrexol with oral folic acid. Proc Am Assoc Cancer Res 33: 406
6. 6. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW (1993) Phase I study of (6R)-5,10-Dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85: 1154-1159
7. 7. Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Buddy AV, Newell DR, Calvert AH (1996) Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 14: 325-335
8. 8. Sessa C, Jong J de, D'Incalci M, Hatty S, Pagani O, Cavilli F (1996) Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin Cancer Res 2: 1123-1127
9. 9. Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R (2000) Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45: 103-110
10. 10. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB (1996) Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res 56: 2331-2335
11. 11. Almassy RJ, Janson CA, Kan CC, Hostomaska Z (1992) Structure of Apo and complexed Escherichia coli glycinamide ribonucleotide transformylase. Proc Natl Acad Sci USA 89: 6114-6118
12. 12. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28: 849-857
13. 13. Boritzki TJ, Barlett CA, Zhang C, Howland EF, Margosiak SA, Palmer CL, Romines WH, Jackson RC (1996) AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 14: 295-303
14. 14. Aylesworth C, Baker SD, Stephenson J, Monroe P, Sanchez I, Walling J, Johnson R, Von Hoff D, Rowinsky E (1998) Phase I and pharmacokinetic (PK) study of the glycinamide ribonucleotide formyltransferase inhibitor LY309887 as a bolus every 3 weeks with folic acid (FA). Proc Am Soc Clin Oncol 17: 225a
15. 15. Budman DR, Barile B, Johnson R, Vinciguerra V, Allen SL, Kolitz J, Kreis W, Zervos P, Walling J (1998) Phase I trial of LY 309887: a specific inhibitor of purine biosynthesis. Proc Am Soc Clin Oncol 17: 224a
16. 16. Wedge SR, Laohavnjj S, Taylor GA, Boddy A, Calvert AH, Newell DR (1995) Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1: 1479-1486